Design Therapeutics, Inc. (NASDAQ: DSGN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 62.46M | Perf Week | -16.34% |
| Market Cap | 766.00M | Forward P/E | - | EPS next Y | -1.56 | Insider Trans | 0.00% | Shs Float | 32.94M | Perf Month | -23.21% |
| Enterprise Value | 559.47M | PEG | - | EPS next Q | -0.38 | Inst Own | - | Short Float | 16.83% | Perf Quarter | -1.61% |
| Income | -70.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 7.96 | Perf Half Y | 19.30% |
| Sales | 0.00 | P/B | 3.78 | EPS next Y | -17.52% | ROA | -32.91% | Short Interest | 5.54M | Perf YTD | 30.49% |
| Book/sh | 3.23 | P/C | 3.69 | EPS next 5Y | - | ROE | -34.03% | 52W High | 17.25 -29.04% | Perf Year | 105.71% |
| Cash/sh | 3.31 | P/FCF | - | EPS past 3/5Y | - | ROIC | -38.92% | 52W Low | 5.28 131.82% | Perf 3Y | 358.43% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 7.04% 4.83% | Perf 5Y | -27.92% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -34.09% | Oper. Margin | 0.00% | ATR (14) | 0.74 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.86 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 31.91 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.86 | EPS Q/Q | 5.88% | SMA20 | -15.81% | Beta | 1.65 | Target Price | 20.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -11.80% | Rel Volume | 3.48 | Prev Close | 12.81 |
| Employees | 55 | LT Debt/Eq | 0.00 | Earnings | Nov 04 | SMA200 | 3.10% | Avg Volume | 733.19K | Price | 12.24 |
| IPO Date | Mar 29, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.06% - | Net Debt/EBITDA | 0.15 | Volume | 2,554,934 | Change | -4.45% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-04-26 | Reiterated | Oppenheimer | Outperform | $18 → $21 |
| Apr-29-26 | Reiterated | Piper Sandler | Overweight | $12 → $20 |
| Jan-07-26 | Initiated | Oppenheimer | Outperform | $18 |
| Dec-03-25 | Initiated | Craig-Hallum | Buy | $15 |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform | $14 |
| Nov-20-25 | Upgrade | RBC Capital | Sector Perform → Outperform | |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight | $42 → $12 |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral | |
| Aug-15-23 | Downgrade | SVB Leerink | Outperform → Market Perform | |
| Aug-15-23 | Downgrade | RBC Capital | Outperform → Sector Perform | $30 → $7.00 |
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 1 | — | — | — | — | |
| Gross Profit | -1 | -1 | -1 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 20 | 18 | 21 | — | — | — | — | |
| Research and Development | 59 | 44 | 57 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | |
| Operating Income | -79 | -62 | -78 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 13 | 11 | — | — | — | — | |
| Net Income Before Taxes | -70 | -50 | -67 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -70 | -50 | -67 | — | — | — | — | |
| Net Income From Continuing Operations | -70 | -50 | -67 | — | — | — | — | |
| Net Income | -70 | -50 | -67 | — | — | — | — | |
| EPS (Recurring) | -1.22 | -0.88 | -1.19 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.22 | -0.88 | -1.19 | — | — | — | — | |
| EPS (Diluted) | -1.22 | -0.88 | -1.19 | — | — | — | — | |
| EBITDA | -69 | -49 | -66 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 57 | 57 | 56 | — | — | — | — | |
| Market Capitalization | 535 | 352 | 148 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| William Arsani | Director | Aug 13 '25 | Sale | 5.25 | 562,627 | 2,953,792 | 1,000,000 | Aug 14 |
| Prasad Deepa | Director | Dec 18 '24 | Sale | 6.27 | 3,806 | 23,864 | 20,000 | Dec 19 |
| William Arsani | Director | Aug 09 '24 | Sale | 4.25 | 814,874 | 3,463,215 | 0 | Aug 12 |
| Schmid John P. | Director | Mar 25 '24 | Buy | 3.74 | 17,809 | 66,606 | 26,965 | Mar 25 |
| Berger Heather A. | Director | Mar 25 '24 | Buy | 3.74 | 1,300 | 4,866 | 1,300 | Mar 25 |
| Schmid John P. | Director | Mar 22 '24 | Buy | 3.62 | 9,156 | 33,133 | 9,156 | Mar 25 |
| LAPPE RODNEY W | Director | Sep 29 '23 | Buy | 2.35 | 21,000 | 49,287 | 133,024 | Oct 02 |
| William Arsani | Director | Mar 30 '21 | Buy | 20.00 | 1,400,000 | 28,000,000 | 2,732,501 | Sep 06 |
| Prasad Deepa | Director | Aug 29 '23 | Buy | 2.31 | 12,000 | 27,670 | 23,806 | Aug 30 |
| William Arsani | Director | Aug 29 '23 | Buy | 2.44 | 1,960,000 | 4,782,400 | 3,000,000 | Aug 30 |
| William Arsani | Director | Aug 28 '23 | Buy | 2.15 | 275,000 | 591,250 | 1,040,000 | Aug 30 |
| Siffert Joao MD | President and CEO | Dec 20 '22 | Buy | 8.38 | 6,300 | 52,763 | 132,619 | Dec 21 |
| Siffert Joao MD | President and CEO | Dec 19 '22 | Buy | 8.47 | 1,150 | 9,741 | 126,319 | Dec 21 |
| George Simeon | Director | Dec 20 '22 | Buy | 8.14 | 40,000 | 325,432 | 6,526,476 | Dec 20 |
| SR One Capital Fund I Aggregator LP | Director | Dec 20 '22 | Buy | 8.14 | 40,000 | 325,432 | 6,526,476 | Dec 20 |